Company Analysis

BioNTech SE (BNTX)

Nasdaq: BNTX · Biological Products, (No Diagnostic Substances) · Mainz, DE · filing with the SEC since 2019
Grade5.9
◀ Past 6.8● Present 5.8▶ Future 5.0
1 est.

Who runs BioNTech SE

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Sahin Ugur
Chief Executive Officer. First filing Mar 2026, latest Oct 9, 2026, 14 filings in all.
Officers reporting now
7
of 15 people with a filing in the last fifteen months
Directors reporting now
8
15 people on the record since 2026
Officerssales are open-market, Oct 9, 2025 to Oct 9, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Sahin UgurChief Executive OfficerMar 2026Oct 9, 202626 · $84.2M
Zapata Gomez RamonChief Financial OfficerMar 2026May 13, 2026none
Poetting SierkChief Operating OfficerMar 2026May 13, 20261 · $5.5M
Hanekamp AnnemarieChief Commercial OfficerMar 2026May 13, 2026none
Jimenez KylieChief People OfficerMar 2026May 13, 2026none
Ryan James Timothy PatrickChief Legal Officer and Chief Business OfficerMar 2026May 13, 2026none
Tureci OzlemChief Medical OfficerMar 2026Mar 18, 2026none
Directorssales are open-market, Oct 9, 2025 to Oct 9, 2026
NameRoleFirst filingLatest filingSales, 12 months
Low-Friedrich Iris KatharinadirectorJun 2026Jun 26, 2026none
Schaffert SusannedirectorJun 2026Jun 26, 2026none
Blackwood Nicola ClairedirectorMar 2026Mar 25, 2026none
Morawietz AnjadirectorMar 2026Mar 25, 2026none
Staudigl RudolfdirectorMar 2026Mar 25, 2026none
Jeggle Helmut WolfgangdirectorMar 2026Mar 18, 2026none
Motschmann MichaeldirectorMar 2026Mar 18, 2026none
Wandschneider UlrichdirectorMar 2026Mar 18, 2026none

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton BNTX · research, not advice